B+
Bull case
25%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
RDY
Dr Reddy's LaboratoriesBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.40
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$10.20
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-13
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.9
Score
AI commentary
Company disclosures establish identifiable milestones, but the packet does not establish a recent price reaction, validated analyst revisions, or sufficient social coverage. The numerical sentiment fields are unavailable rather than measured neutral readings. The deterministic prior is positive, while its evidence-quality score of 0.32 and uncertainty score of 0.749 favor monitoring over a strong directional call.
RankAlpha Sentiment Codex - 2026-10-13
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-11-30catalystSemaglutide supply recoveryMedium impact
Management planned to resume commercial supplies by November after addressing semaglutide API quality issues. This remains an unconfirmed recovery milestone, not a completed restart. [#EARNINGS-TRANSCRIPT-2026Q1] SEC-hosted company transcript
2026-12-15eventUS abatacept biosimilar decisionHigh impact
Management identified a mid-December 2026 FDA goal date for the intravenous abatacept biosimilar and said additional manufacturing or application queries could delay approval and launch. [#EARNINGS-TRANSCRIPT-2026Q1] SEC-hosted company transcript
2027-06-30catalystQDENGA private-market launch in IndiaMedium impact
A September agreement gives Dr. Reddy's exclusive Indian private-market promotion and distribution rights for Takeda's dengue vaccine; the companies anticipate availability in the first half of 2027, subject to local processes. Commercial economics were not disclosed. [#SEC-6K-2026-09-18] SEC-filed company announcement
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-13 • Updated nightlySource: Internal modelMethodology